SRX Global takes stake in neuroscience firm Vistagen

What's the deal? SRX Global has acquired a stake in Vistagen TherapeuticsDealroom has a profile for this one. Try Dealroom →, a late clinical-stage biopharmaceutical company listed on the Nasdaq. The move was announced on August 4, 2026, from SRX's base in North Palm Beach, Florida.

What each company does: SRX Global describes itself as an AI-enabled platform that invests in operating companies and strategic assets to generate long-term shareholder value. Vistagen develops intranasal product candidates called pherines, using what it calls nose-to-brain neurocircuitry.

What's the endgame? SRX says it targets high-conviction investments. The Vistagen stake adds a neuroscience play to its portfolio, though the size of the stake and financial terms were not disclosed.

The signal: The deal shows an AI-focused investment platform extending into clinical-stage biopharma. Without disclosed terms, its strategic weight remains unclear.

Read more: Aktiencheck

Image credit: foteih